Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 1 to 10 of 87

TitleType
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]Technology appraisal guidance
Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [TSID12394]Technology appraisal guidance
Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent careHealthTech guidance
Artificial intelligence (AI)-derived software to help clinical decision making in strokeHealthTech guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Technology appraisal guidance
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All